Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location
about
Emerging Threats in Antifungal-Resistant Fungal PathogensAdvances in the treatment of invasive neonatal candidiasisGain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulenceEpidemiology of invasive candidiasis: a persistent public health problemAntifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates.Canadian clinical practice guidelines for invasive candidiasis in adults.Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.Patterns of human oral yeast species distribution on Hainan Island in China.Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazoleTrends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.Developments in the epidemiolgy of invasive fungal infections - implications for the empiric and targeted antifungal therapy.Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.Inner kinetochore of the pathogenic yeast Candida glabrata.Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costsThe epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).Risk factors for fluconazole-resistant candidemia.Caspofungin activity against clinical isolates of fluconazole-resistant Candida.In Vitro Activity of Caspofungin Against Fluconazole-Resistant Candida Species Isolated From Clinical Samples in Iran.Comparative Genomics of Two Sequential Candida glabrata Clinical Isolates.Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata.Susceptibility to antifungal agents of Candida species isolated from paediatric and adult patients with haematological diseases.Candida glabrata's Genome Plasticity Confers a Unique Pattern of Expressed Cell Wall Proteins.Multilocus Sequence Typing (MLST) Genotypes of Bloodstream Isolates in Korea: Association With Antifungal Resistance, Mutations in Mismatch Repair Gene (Msh2), and Clinical Outcomes
P2860
Q26750816-8BEE2600-4863-4DE1-972D-D9733CB01093Q27022585-9770F067-13C4-4DF5-8FE9-55460445C625Q27318203-9FB6B175-6726-471F-84AC-9197F6E22A47Q29616758-AB997489-1B8F-4CED-A40A-43FA4EBDF958Q30452376-D3BF7BBF-D17D-4207-8C97-1A0842470922Q33805788-B3C77BA8-DE3D-406B-94BD-2573D5B0BF09Q34045265-245A603B-D599-4FE5-A96E-28DFBA077B4FQ34237335-B45847B3-A0FB-4D30-9FE0-E5CD4652F6EAQ34430768-36211D78-8690-4B06-9475-7986A251C9A9Q35004311-7DD1C0E5-6F9E-4881-B800-347A29D00B6AQ35714132-0199A706-A32A-4016-9EDF-4CE428683E04Q36521993-249886BF-7380-4D15-A34C-A28E7070278BQ36898200-E9783FDB-2484-41C8-9BA3-DD5A99C62A9FQ37159565-32B4E376-BAFB-46CF-9A42-A7CD4610ACBDQ37374850-963555DC-49EA-4528-94A2-2F4FF78A4815Q37489291-9E023132-D9C3-4622-ABF8-27AA35B8538CQ37579551-FE106852-4EFD-4AC6-B303-153D229D97C3Q38475730-86A93C99-59C9-4AFD-B3F1-8050B6F87E13Q39375216-36AE8BC4-7431-4411-96D9-B6F5EC2A867FQ39934814-3A323114-E9A0-4E34-8D02-47828F8D425FQ40404311-F31B4122-A767-4D29-B7D7-2D526AB43DBBQ41024436-EF4B7235-404B-4CE4-9B3A-21A71BDCA431Q41380754-BAFE063F-B338-41F0-B183-4BA152C96FEBQ43701370-93F292F9-1F45-4F40-8E7E-A5470EF23053Q46724334-4CE5814C-AC51-487F-A546-AD9D281A5426Q46785730-C47FDDBD-2E6D-45D3-9654-FED44C1B48ABQ55488580-C9A9FAB1-B5B0-4797-B110-6D3E6FC4DFE2Q57214733-4C1C4711-561A-4448-AFA7-95232A4707EC
P2860
Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Variation in susceptibility of ...... nt age and geographic location
@ast
Variation in susceptibility of ...... nt age and geographic location
@en
type
label
Variation in susceptibility of ...... nt age and geographic location
@ast
Variation in susceptibility of ...... nt age and geographic location
@en
prefLabel
Variation in susceptibility of ...... nt age and geographic location
@ast
Variation in susceptibility of ...... nt age and geographic location
@en
P2093
P2860
P1476
Variation in susceptibility of ...... nt age and geographic location
@en
P2093
D J Diekema
M A Pfaller
R J Hollis
S A Messer
S Tendolkar
P2860
P304
P356
10.1128/JCM.41.5.2176-2179.2003
P407
P577
2003-05-01T00:00:00Z